A functional yeast survival screen of tumor-derived cDNA libraries designed to identify anti-apoptotic mammalian oncogenes

Yeast cells can be killed upon expression of pro-apoptotic mammalian proteins. We have established a functional yeast survival screen that was used to isolate novel human anti-apoptotic genes overexpressed in treatment-resistant tumors. The screening of three different cDNA libraries prepared from metastatic melanoma, glioblastomas and leukemic blasts allowed for the identification of many yeast cell death-repressing cDNAs, including 28% of genes that are already known to inhibit apoptosis, 35% of genes upregulated in at least one tumor entity and 16% of genes described as both anti-apoptotic in function and upregulated in tumors. These results confirm the great potential of this screening tool to identify novel anti-apoptotic and tumor-relevant molecules. Three of the isolated candidate genes were further analyzed regarding their anti-apoptotic function in cell culture and their potential as a therapeutic target for molecular therapy. PAICS, an enzyme required for de novo purine biosynthesis, the long non-coding RNA MALAT1 and the MAST2 kinase are overexpressed in certain tumor entities and capable of suppressing apoptosis in human cells. Using a subcutaneous xenograft mouse model, we also demonstrated that glioblastoma tumor growth requires MAST2 expression. An additional advantage of the yeast survival screen is its universal applicability. By using various inducible pro-apoptotic killer proteins and screening the appropriate cDNA library prepared from normal or pathologic tissue of interest, the survival screen can be used to identify apoptosis inhibitors in many different systems

Das 20S Proteasom in Astrozyten und seine Rolle bei Entzündungsprozessen im Zentralnervensystem

Das Proteasom ist das zentrale proteolytische System in eukaryontischen Zellen, welches die Mehrzahl der intrazellulären Proteine abbaut. Da viele essentielle Prozesse in der Zelle proteolytisch reguliert werden, besitzt das Proteasom eine außerordentliche biologische Bedeutung. Die Erforschung des Proteasoms im ZNS steht erst am Anfang, dennoch zeigen zahlreiche Untersuchungen, dass Inhibition bzw. Störung des Ubiquitin-Proteasom-Systems mit vielen neurologischen oder neurodegenerativen Erkrankungen einhergeht. Deshalb wurde in der vorliegenden Arbeit nach Veränderungen des Proteasoms in Entzündungsprozessen im ZNS am Beispiel der experimentellen autoimmunen Encephalomyelitis (EAE) in der Maus gesucht. Schwerpunkt der Untersuchungen war das Proteasom in Astrozyten. Astrozyten stellen die größte Gruppe unter den Gliazellen dar und besitzen vielfältige Funktionen, zu denen neben klassischen housekeeping Funktionen auch Aufgaben bei der Immunantwort zählen. Der enge und für Neurone essentielle Kontakt prädestiniert Astrozyten, neuronale Erkrankungen mit auszulösen und zu modulieren. In dieser Arbeit wurden in primär isolierten Astrozyten Immunproteasomen (IP) detektiert. Durch Experimente mit der Astrozytenzelllinie TSA-3 konnte gezeigt werden, dass Astrozyten im unstimulierten Zustand nur Standardproteasom besitzen, auf Stimulation jedoch mit der Bildung von IP reagieren. Das Fehlen von IP in Astrozyten unter in vivo Bedingungen deckte sich mit den Strukturanalysen von Proteasomen aus dem Großhirn von Mäusen verschiedener Altersstufen, den mRNA-Expressionsanalysen sowie immunhistologischen Untersuchungen von Hirngewebe aus EAE Mäusen. Die aus dem Großhirn isolierten Proteasomen nach Induktion einer EAE durch Myelin-Oligodendrocyten-Glycoprotein (MOG) enthielten keine IP. Dennoch erfolgt eine Aktivitätsveränderung im Proteasom vor dem Auftreten der ersten EAE Symptome, die in vitro zu einer effizienteren Epitopgenerierung aus einem MOG-Peptid führt.The proteasome is the central proteolytic system in all eukaryotic cells catalysing the degradation of the majority of intracellular proteins. Since many essential processes are proteolytically controlled, the proteasome is of crucial biological importance. Yet numerous investigations show that many neurological or neurodegenerative diseases go along with inhibition and/or changes of the ubiquitin-proteasome-system. Therefore the present thesis investigates the proteasome system during inflammatory processes in the CNS, namely during experimental autoimmune encephalomyelitis (EAE), a widely used animal model for human multiple sclerosis. Main focus of the investigations was the proteasome in astrocytes. Astrocytes embody the largest group of glial cells in the CNS and possess various functions. Apart from classical housekeeping functions astrocytes take part in the immune reaction in the CNS. Their close and essential contact to neurons predestines astrocytes to cause and modulate neural diseases. In the present work immune proteasome subunits were detected in primary astrocytes isolated from newborn mice. On the other hand, when grown under resting conditions the murine astrocyte cell line, TSA-3, contains standard proteasome only, however, when treated with interferon gamma, these cells produce immune proteasomes, too. Subunit analyses of proteasomes isolated from the cerebrum of mice of different age, measurement of the mRNA expression level of proteasome subunits as well as immune-histological investigations of brain tissue from mice confirmed the absence of immune proteasome in astrocytes under in vivo conditions. Proteasomes isolated from mouse brain after induction of EAE by active immunization with myelin oligodendrocyte glycoprotein (MOG) did not contain immune subunits. Nevertheless an activity change in the proteasomes isolated from brains before onset of EAE was observed, which lead to a more efficient epitope generation from MOG peptide

A Functional Yeast Survival Screen of Tumor-Derived cDNA Libraries Designed to Identify Anti-Apoptotic Mammalian Oncogenes

<div><p>Yeast cells can be killed upon expression of pro-apoptotic mammalian proteins. We have established a functional yeast survival screen that was used to isolate novel human anti-apoptotic genes overexpressed in treatment-resistant tumors. The screening of three different cDNA libraries prepared from metastatic melanoma, glioblastomas and leukemic blasts allowed for the identification of many yeast cell death-repressing cDNAs, including 28% of genes that are already known to inhibit apoptosis, 35% of genes upregulated in at least one tumor entity and 16% of genes described as both anti-apoptotic in function and upregulated in tumors. These results confirm the great potential of this screening tool to identify novel anti-apoptotic and tumor-relevant molecules. Three of the isolated candidate genes were further analyzed regarding their anti-apoptotic function in cell culture and their potential as a therapeutic target for molecular therapy. PAICS, an enzyme required for <i>de novo</i> purine biosynthesis, the long non-coding RNA <i>MALAT1</i> and the MAST2 kinase are overexpressed in certain tumor entities and capable of suppressing apoptosis in human cells. Using a subcutaneous xenograft mouse model, we also demonstrated that glioblastoma tumor growth requires MAST2 expression. An additional advantage of the yeast survival screen is its universal applicability. By using various inducible pro-apoptotic killer proteins and screening the appropriate cDNA library prepared from normal or pathologic tissue of interest, the survival screen can be used to identify apoptosis inhibitors in many different systems.</p></div